A Glance into the Future of Myositis Therapy

Overview

Journal Ther Adv Musculoskelet Dis

Date 2022 May 31

PMID 35634354

Authors

Ilaria Chiapparoli

Claudio Galluzzo

Carlo Salvarani

Nicolo Pipitone

Affiliations

Soon will be listed here.

Abstract

The idiopathic inflammatory myopathies are chronic diseases of the skeletal muscle that comprise various conditions, including dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and the antisynthetase syndrome. Although there are a number of distinguishing features, all these disorders are characterized by an immune and inflammatory response mainly directed against the muscle. Hence, therapy is geared toward curbing the autoimmune and inflammatory response. A quite wide range of medications are currently available to treat these disorders, but despite all therapeutic progress still a number of patients are unable to maintain a sustained remission. In this review article, we have marshaled a variety of potential therapeutic agents that may hold promise for the future treatment of the idiopathic inflammatory myopathies. It is to be expected that by increasing the therapeutic armamentarium with agents that have different mechanisms of action even challenging cases could be successfully managed, thus reducing disease burden and disability.

Citing Articles

Anti-MDA5 Amyopathic Dermatomyositis-A Diagnostic and Therapeutic Challenge.

Bobirca A, Alexandru C, Musetescu A, Bobirca F, Florescu A, Constantin M Life (Basel). 2022; 12(8).

PMID: 35892910 PMC: 9329888. DOI: 10.3390/life12081108.

References

Burstein S . Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum. Mol Pharmacol. 2020; 99(2):125-132. DOI: 10.1124/molpharm.120.000083. View

Granel B, Daumas A, Jouve E, Harle J, Nguyen P, Chabannon C . Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Ann Rheum Dis. 2014; 74(12):2175-82. PMC: 4680117. DOI: 10.1136/annrheumdis-2014-205681. View

Pinal-Fernandez I, Kroodsma C, Mammen A . Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome. Rheumatology (Oxford). 2019; 58(7):1307-1308. PMC: 6821353. DOI: 10.1093/rheumatology/kez020. View

Paik J, Casciola-Rosen L, Shin J, Albayda J, Tiniakou E, Leung D . Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients. Arthritis Rheumatol. 2020; 73(5):858-865. PMC: 8084900. DOI: 10.1002/art.41602. View

Higgs B, Zhu W, Morehouse C, White W, Brohawn P, Guo X . A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2013; 73(1):256-62. PMC: 3888620. DOI: 10.1136/annrheumdis-2012-202794. View

Tjarnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasova Studynkova J . Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2017; 77(1):55-62. DOI: 10.1136/annrheumdis-2017-211751. View

He J, Zhang R, Shao M, Zhao X, Miao M, Chen J . Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2019; 79(1):141-149. PMC: 6937406. DOI: 10.1136/annrheumdis-2019-215396. View

Li T, Guo L, Chen Z, Gu L, Sun F, Tan X . Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep. 2016; 6:33226. PMC: 5018967. DOI: 10.1038/srep33226. View

Umezawa N, Kawahata K, Mizoguchi F, Kimura N, Yoshihashi-Nakazato Y, Miyasaka N . Interleukin-23 as a therapeutic target for inflammatory myopathy. Sci Rep. 2018; 8(1):5498. PMC: 5882883. DOI: 10.1038/s41598-018-23539-4. View

10.

Smith L, Paik J . Promising and Upcoming Treatments in Myositis. Curr Rheumatol Rep. 2020; 22(10):65. PMC: 7955788. DOI: 10.1007/s11926-020-00943-2. View

11.

Paudyal A, Zheng M, Lyu L, Thapa C, Gong S, Yang Y . JAK-inhibitors for dermatomyositis: A concise literature review. Dermatol Ther. 2021; 34(3):e14939. DOI: 10.1111/dth.14939. View

12.

Venalis P, Lundberg I . Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2013; 53(3):397-405. DOI: 10.1093/rheumatology/ket279. View

13.

Delvino P, Bartoletti A, Monti S, Biglia A, Montecucco C, Carducci M . Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology (Oxford). 2020; 59(12):4003. DOI: 10.1093/rheumatology/keaa377. View

14.

Allenbach Y, Benveniste O, Stenzel W, Boyer O . Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020; 16(12):689-701. DOI: 10.1038/s41584-020-00515-9. View

15.

Kim Y, Schiopu E, Danko K, Mozaffar T, Chunduru S, Lees K . A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. J Am Acad Dermatol. 2020; 84(4):1160-1162. DOI: 10.1016/j.jaad.2020.07.122. View

16.

Langlois V, Gillibert A, Uzunhan Y, Chabi M, Hachulla E, Landon-Cardinal O . Rituximab and Cyclophosphamide in Antisynthetase Syndrome-related Interstitial Lung Disease: An Observational Retrospective Study. J Rheumatol. 2020; 47(11):1678-1686. DOI: 10.3899/jrheum.190505. View

17.

Lai Y, Wei X, Ye T, Hang L, Mou L, Su J . Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases. Front Immunol. 2021; 12:747335. PMC: 8602099. DOI: 10.3389/fimmu.2021.747335. View

18.

Iannone F, Scioscia C, Falappone P, Covelli M, Lapadula G . Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006; 33(9):1802-4. View

19.

Greenberg S . Type 1 interferons and myositis. Arthritis Res Ther. 2010; 12 Suppl 1:S4. PMC: 2991777. DOI: 10.1186/ar2885. View

20.

Bitar C, Maghfour J, Ho-Pham H, Stumpf B, Boh E . Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients. JAAD Case Rep. 2019; 5(2):191-194. PMC: 6357541. DOI: 10.1016/j.jdcr.2018.11.019. View